• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      GSK India to Ally with Two More Japan Firms

      Posted AtBusiness-Standard

      Close on the heels of signing a co-promotion pact with the Japanese pharma major Eisai Pharma to market an anti-ulcer drug in India, Glaxo SmithKline Pharmaceuticals India (GSK India) is planning to sign up pacts with two more Japanese companies for similar arrangements in different therapeutic segments.

      The new product licensing proposals are in the therapeutic segments of ICU-based cardiovascular therapy and diabetology.

      A senior GSK India executive said the company was in talks with the Japanese companies and the marketing pacts were likely to be signed in the first quarter of 2006.

      "We have already identified the brands and the alliance discussions are progressing with the companies in Japan. We hope, the products could be rolled out in the Indian market in the financial year 2006 itself ," he said. However, he declined to reveal the identity of the firms.

      The company sources said it was in discussion with Eisai Pharma for licensing one more product for the Indian market. GSK India, following the earlier co-marketing alliance signed with Eisai, is currently marketing Paritec, a new generation anti-ulcer drug in India.

      As part of its market expansion plan, the company has been exploring opportunities for licensing new products in line with its portfolio. In addition to the domestic market growth plan, the company is also exploring options such as brands and company acquisitions in the domestic as well as overseas markets.

      GSK Pharma sources said it planned to enter into more in-licensing agreements and alliances for upgrading the technology in the manufacturing of new lifestyle products such as cardiovascular, central nervous system and Diabetes.

      The company's present market strategy is in line with the changing demographics, which has altered the earlier tropical nature of disease profile in India, and the current scenario towards lifestyle drugs in cardiovascular, psychiatry, neurology, gynecology, and diabetology segments more in line with the western countries.

      GSK India has 6.5 per cent market share in the domestic pharma market at present, depicting an overall sales growth of 7.7 per cent. The sales growth in particularly pharma segment is 8.7 per cent.

      Augmentin remains GSK's No.1 power brand and the other leading brands are Vozet and Cetzine. The company also now enjoys leadership position in vaccines and the therapeutic segments of dermatology, corticosteroids and thyroid.

      The global parent "Glaxo SmithKline Pharmaceuticals Plc (GSK Plc)" had recently joined hands with the University of Oxford to initiate clinical research for new oncology products to be conducted in India.

      The sources said more such projects are likely to come to India for other therapeutic areas in association few other global institutions.

      December 19, 2005


      Share this Article!

    Back to top^